In what could turn out to be its largest acquisition ever, generic drug giant Mylan on Wednesday went public with a bid for competing Ireland-based drugmaker Perrigo Co. in a deal valued at about $30 billion.

The proposal, offering $205 a share in an unspecified combination of cash and stock, was contained in a letter from Mylan chairman Robert Coury delivered to Perrigo CEO Joseph Papa on Monday. Mylan released the letter Wednesday morning.

Mr. Coury’s letter indicated that joining forces with Perrigo would nearly double Mylan’s revenue, which was $7.7 billion in 2014.

If the deal were to go through as proposed, it would be similar in size to the 2013 acquisition of Pittsburgh’s H.J. Heinz Co. by Berkshire Hathaway and 3G Capital for about $28 billion. Both the pharmaceuticals and food industries have being undergoing consolidation in recent years.

Advertise with us

Perrigo, based in Dublin, issued a brief statement Wednesday afternoon acknowledging the “unsolicited” proposal, saying, “The board of Perrigo will meet to discuss the proposal and a further announcement will be made when appropriate.”

Shares of both companies surged on the news. Mylan’s stock added $8.79, or 14.76 percent, to close Wednesday at $68.36. Perrigo jumped $30.29, or 18.39 percent, to close at $195.

Industry analysts have considered Perrigo a potential takeover target.

“Perrigo remains among the few last sizable generic firms with unique niche attributes,” including private-label over-the-counter products and prescription topicals, Morningstar analyst Michael Waterhouse wrote in a note to clients.

It’s possible Mylan’s proposal could spark a bidding war, he said.

Advertise with us

“If Perrigo goes up for sale, we imagine other competitors like Teva, Actavis and Valeant could be interested as well,” Mr. Waterhouse said. He said Mylan’s $205-per-share offer “seems high, but reasonable.”

In his letter, Mr. Coury said a combination of the two companies made “compelling strategic sense.”

“We have complementary operations across all of our businesses, both from a product and geographic perspective,” he said. “The combination of our companies would result in an unmatched global platform.”

Mr. Coury, who said the two companies have had a number of discussions about a possible merger, offered Mr. Papa a position as co-chairman and a seat on the combined company’s board. He said Mylan CEO Heather Bresch and President Rajiv Malik would continue in those roles.

In addition to generic pharmaceuticals, Perrigo makes branded and private-label over-the-counter health care products, vitamins and nutritional products.

Advertise with us

If Mylan is successful, the acquisition of Perrigo would come on the heels of the roughly $5.3 billion purchase of a major portion of Abbott Laboratories’ non-U.S. operations. Mylan also has a deal pending to buy certain women’s health care businesses from Famy Care in Mumbai, India, for about $750 million in cash.

As part of the Abbott transaction, Mylan reincorporated overseas to cut its tax bill in a controversial move known as an inversion. The company’s executive offices remain in Cecil, Washington County.

Perrigo also underwent an inversion, in late 2013, when it acquired the Irish biotech firm Elan Corp. The company continues to operate from the U.S., from its former headquarters in Allegan, Mich.